Equity Issuances

Indivior Pharmaceuticals, Inc. issued convertible note to initial purchasers for $500,000,000 principal amount.

“Section 13(a) of the Exchange Act. ☐ Item 1.01. Entry Into a Material Definitive Agreement. Indenture On March 17, 2026, Indivior Pharmaceuticals, Inc. (the “ Company ”) issued $500,000,000 principal amount of its 0.625% Convertible Senior Notes due 2031 (the “ Notes ”; the “ Convertible Notes Offering ”). The Notes were issued pursuant to, and are governed by, an”

AMERICAN REBEL HOLDINGS INC issued shares issuable upon conversion at a discount of 25% of the market price of convertible note to 1800 Diagonal Lending, LLC for loan of $124,200, resulting in net proceeds of $100,000.

“Diagonal Lending, LLC, an accredited investor (the “Lender”), pursuant to which the Lender made a loan to the Company, evidenced by a promissory note in the principal amount of $124,200 (the “Note”). An original issue discount of $16,200 and fees of $8,000 were applied on the issuance date, resulting in net loan proceeds to the Company of $100,000. Accrued,”

AMERICAN REBEL HOLDINGS INC issued 70,000 shares of Series D Convertible Preferred Stock of preferred stock to an accredited investor for $7.50 per share for cash consideration of $525,000.

“On March 12, 2026, the Company sold 70,000 shares of Series D Convertible Preferred Stock at $7.50 per share to an accredited investor for cash consideration of $525,000.”

Longevity Health Holdings, Inc. issued 689,656 shares of common stock to International Capital Partners LLC for $0.29 per Share for an aggregate purchase price of approximately $200,000.

“entered into a Common Stock Purchase Agreement (the “Stock Purchase Agreement”) with International Capital Partners LLC, a Florida limited liability company (the “Purchaser”), pursuant to which the Company has agreed to sell, and the Purchaser has agreed to purchase, in a private placement (the “Offering”) 689,656 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (“Common Stock”), at a purchase price of $0.29 per Share for an aggregate purchase price of approximately $200,000.”

i-80 Gold Corp. issued 8,895 common shares of common stock to John Seaman.

“John Seaman, a director of the Company, held convertible debentures in the principal amount of $50,000 and received 8,895 common shares upon conversion of accrued interest.”

i-80 Gold Corp. issued 2,993,307 common shares of common stock to Orion Mine Finance Fund III LP.

“The 2,993,307 common shares were issued to Orion Mine Finance Fund III LP in partial satisfaction of the Company’s obligations under the Convertible Loan and the termination of the Convertible Loan in a transaction exempt from registration under the Securities Act by virtue of Section 3(a)(9) thereof because no commission or other remuneration was paid in connection with the transaction.”

i-80 Gold Corp. issued 8,133,983 common shares of common stock.

“The 8,133,983 common shares issued upon conversion of accrued interest of the convertible debentures were issued in transactions exempt from registration under the Securities Act by virtue of Section 3(a)(9) thereof because no commission or other remuneration was paid in connection with conversion of the notes and any resulting issuance of common shares.”

Verses AI Inc. issued 75,546 finder warrants of warrant to certain finders located outside of the United States for services as finders, no additional cash consideration.

“In connection with the Offering, the Company paid aggregate cash finders’ fees of C$16,160 (approximately US$11,866) and issued an aggregate of 75,546 finder warrants (each, a “ Finder Warrant ”) to certain finders located outside of the United States, who assisted the Company with the offer and sale of Units to purchasers who were not “U.S. persons” as defined in Regulation S under the U.S. Securities Act (as defined below).”

Verses AI Inc. issued 1,170,807 units, each unit consisting of one Class A Subordinate Voting Share and one-half of one share purchase warrant of unit to various investors for C$745,805 (approximately US$547,644) in cash and extinguishment of C$132,300 (approximately US$97,148) in liabilities.

“On March 13, 2026, Verses AI Inc. (the “Company”) closed a non-brokered private placement offering of 1,170,807 units (the “Units”) of the Company at a price of C$0.75 (US$0.55) per Unit (the “Offering”). Pursuant to the Offering, the Company raised gross cash proceeds of C$745,805 (approximately US$547,644) through the issuance of 994,407 Units, before deducting commissions and expenses incurred in connection with the Offering, and extinguished C$132,300 (approximately US$97,148) in liabilities through the issuance of 176,400 Units.”

Golub Capital BDC 4, Inc. issued 3,500,503.191 shares of the Company's common stock of common stock to accredited investors for $52.51 million aggregate.

“On March 16, 2026, Golub Capital BDC 4, Inc. (the “Company”) delivered a capital drawdown notice to its stockholders relating to the sale of 3,500,503.191 shares of the Company's common stock, par value $0.001 per share (the “Common Stock”), for an aggregate offering price of $52.51 million.”

North Haven Net REIT issued 111,568 Class I shares of common stock to a feeder vehicle primarily created to hold certain classes of the Company's common shares for $2,294,000.

“As of March 2, 2026, North Haven Net REIT, a Maryland statutory trust (the “Company”), sold an aggregate of 111,568 Class I shares (the "Shares") (with the final number of Shares being determined on March 13, 2026) for aggregate consideration of approximately $2,294,000, based on the net asset value per share as of February 28, 2025, to a feeder vehicle primarily created to hold certain classes of the Company's common shares.”

INTEGRATED RAIL & RESOURCES INC. issued 7,056 shares of Series A Convertible Preferred Stock of preferred stock to B H, Inc. for full satisfaction and discharge of $705,589 in outstanding indebtedness.

“on March 9, 2026, the Company issued 7,056 shares of Series A Convertible Preferred Stock to the Buyer in full satisfaction and discharge of $705,589 in outstanding indebtedness”

Pono Capital Four, Inc. issued 190,000 units (the “Private Units”) of unit to the Sponsor and a certain institutional investor (the “Private Placement Investor”) for $10.00 per Private Unit.

“Simultaneously with the closing of the IPO, the Company consummated a private placement (the “Private Placement”) of an aggregate of 190,000 units (the “Private Units”) to the Sponsor and a certain institutional investor (the “Private Placement Investor”), at a price of $10.00 per Private Unit, generating total proceeds of $1,900,000.”

PAR TECHNOLOGY CORP issued a maximum of 16,719,221 shares of Common Stock of convertible note to qualified institutional buyers.

“Initially, a maximum of 16,719,221 shares of Common Stock may be issued upon conversion of the Notes based on the initial maximum conversion rate of 63.0914 shares of Common Stock per $1,000 principal amount of Notes.”

Agassi Sports Entertainment Corp. issued 80,000 shares of restricted common stock of common stock to two accredited investors (the "Investors"), including Boreta Lifetime Trust for $5.00 per share, or a total of $400,000.

“with two accredited investors (the “ Investors ”), pursuant to which the Investors purchased an aggregate of 80,000 shares of restricted common stock from the Company, for $5.00 per share, or a total of $400,000. The Subscription Agreements included customary representations and warranties of the Investors and the Company. One of the Investors was the”

TALPHERA, INC. issued pre-funded warrants to purchase up to an aggregate of 6,399,316 shares of common stock of warrant to institutional investors and a member of management for $0.585 per pre-funded warrant.

“On March 6, 2026, the Company achieved the conditions of subsection 2.4(a)(i) of the Purchase Agreement to effect the third closing of the private placement and, on March 13, 2026, issued and sold to the Purchasers who did not participate in the Optional Closing (collectively, the Third Closing): ● 639,931 shares of common stock at a purchase price of $0.586 per share; and ● Pre-funded warrants at a purchase price of $0.585 per pre-funded warrant to purchase up to an aggregate of 6,399,316 shares of common stock at an exercise price of $0.001 per share.”

TALPHERA, INC. issued 639,931 shares of common stock of common stock to institutional investors and a member of management for $0.586 per share.

“On March 6, 2026, the Company achieved the conditions of subsection 2.4(a)(i) of the Purchase Agreement to effect the third closing of the private placement and, on March 13, 2026, issued and sold to the Purchasers who did not participate in the Optional Closing (collectively, the Third Closing): ● 639,931 shares of common stock at a purchase price of $0.586 per share; and ● Pre-funded warrants at a purchase price of $0.585 per pre-funded warrant to purchase up to an aggregate of 6,399,316 shares of common stock at an exercise price of $0.001 per share.”

PetVivo Holdings, Inc. issued One Million Eight Hundred Seventy-Five Thousand shares of Restricted Common Stock of common stock to the investor for One Million Five Hundred Thousand Dollars ($1,500,000) of equity financing.

“the investor received a purchase option to invest an additional One Million Five Hundred Thousand Dollars ($1,500,000) of equity financing in exchange for One Million Eight Hundred Seventy-Five Thousand shares of Restricted Common Stock of the Company pursuant to the same terms and conditions; this additional equity financing is anticipated to be received on or before June 30, 2026.”

PetVivo Holdings, Inc. issued 1,250,000 shares of Restricted Common Stock of common stock to accredited investor for $1,000,000 equity financing.

“PetVivo Holdings, Inc., including its wholly-owned subsidiaries PetVivo Animal Health and PetVivo AI, Inc., (collectively the "Company", "we" and "us") entered into a Subscription Agreement to receive One Million Dollars ($1,000,000) of equity financing in exchange for One Million Two Hundred Fifty Thousand (1,250,000) shares of Restricted Common Stock of the Company ("Shares") (the "Offering").”

Acumen Pharmaceuticals, Inc. issued 10,833,331 shares of common stock to certain institutional accredited investors named therein for $3.30 per Share.

“On March 13, 2026, Acumen Pharmaceuticals, Inc. (the “ Company ”) entered into a Securities Purchase Agreement (the “ Purchase Agreement ”) with certain institutional accredited investors named therein (each, an “ Investor ” and collectively, the “ Investors ”), pursuant to which the Company agreed to sell to the Investors, in a private placement (the “ Private Placement ”), 10,833,331 shares (the “ Shares ”) of the Company’s common stock, par value $0.0001 per share (the “ Common Stock ”), at an offering price of $3.30 per Share.”

zSpace, Inc. issued convertible note to an institutional investor for original principal amount of $4,301,075.

“On the Second Closing, the Company will issue an additional Note in the original principal amount of $4,301,075 (the “Additional Note”).”

CRISPR Therapeutics AG issued 11,363,580 Common Shares may be delivered upon conversion of the Notes of convertible note to qualified institutional buyers for $600.0 million aggregate principal amount of Convertible Senior Notes due 2031.

“any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 1.01. Entry into a Material Definitive Agreement. On March 16, 2026, CRISPR Therapeutics AG (the “Company”) completed its previously announced private offering (the “Offering”) of $600.0 million aggregate principal amount of its Convertible Senior”

Cottonwood Communities, Inc. issued 137,655 shares of Series 2025 Preferred Stock of preferred stock to accredited investors for aggregate proceeds of $1,374,000.

“During the period from March 4, 2026 through March 15, 2026, we issued and sold 137,655 shares of Series 2025 Preferred Stock in the Series 2025 Private Offering and received aggregate proceeds of $1,374,000.”

Local Bounti Corporation/DE issued 5,500,000 shares of common stock of warrant to U.S. Bounti, LLC for $0.125 per share exercise price.

“The Warrant is exercisable immediately at an exercise price of $0.125 per share of Common Stock and will expire 10 years from the initial exercise date.”

Local Bounti Corporation/DE issued 6,000,000 shares of common stock (if converted) of convertible note to U.S. Bounti, LLC for $15.0 million principal note with 7.0% PIK interest.

“On March 13, 2026, Local Bounti Corporation, a Delaware corporation (the “Company”), entered into a Convertible Note and Warrant Purchase Agreement (the “Purchase Agreement”) with U.S. Bounti, LLC (the “Purchaser”), providing for the purchase, sale and issuance of (i) a convertible note with an initial principal balance of $15.0 million (the “Note”) and (ii) a common stock purchase warrant (the “Warrant”) pursuant to which the Purchaser has the right to purchase and acquire 5,500,000 shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”).”

C2 Blockchain, Inc. issued 4,500,000 shares of preferred stock to Levi Jacobson.

“On March 11, 2026, the Board of Directors of the Company approved the issuance of 4,500,000 shares of the Company’s Series A Preferred Stock to Levi Jacobson, the Company’s sole officer and director.”

C2 Blockchain, Inc. issued 3,000,000 shares of common stock to accredited investor for $0.01 per share for aggregate gross proceeds of $30,000.

“On March 9, 2026, the Company entered into a subscription agreement with an accredited investor for the purchase of 3,000,000 shares of the Company’s common stock at a purchase price of $0.01 per share for aggregate gross proceeds of $30,000.”

Alto Neuroscience, Inc. issued pre-funded warrants to purchase 3,100,000 shares of Common Stock of warrant to institutional investors for purchase price for the Pre-Funded Warrants is the Purchase Price minus $0.0001 per Pre-Funded Warrant.

“to sell and issue to the Purchasers in a private placement transaction (the “ Private Placement ”) (i) 2,900,000 shares (the “ Shares ”) of the Company’s common stock, par value $0.0001 (“ Common Stock ”), and (ii) with respect to certain Purchasers, pre-funded warrants to purchase 3,100,000 shares of Common Stock (the “ Pre-Funded Warrants ”) in lieu of Shares.”

Alto Neuroscience, Inc. issued 2,900,000 shares of common stock to institutional investors for $20.00 per share.

“Purchasers, pre-funded warrants to purchase 3,100,000 shares of Common Stock (the “ Pre-Funded Warrants ”) in lieu of Shares. The purchase price per share of Common Stock is $20.00 per share (the “ Purchase Price ”) and the purchase price for the Pre-Funded Warrants is the Purchase Price minus $0.0001 per Pre-Funded Warrant. The Company anticipates receiving”

Metals Acquisition Corp. II issued 5,066,666 warrants of warrant to Sponsor, Sternship and the Underwriters for $1.50 per Private Placement Warrant, generating gross proceeds to the Company of $7,600,000.

“On March 13, 2026, simultaneously with the closing of the IPO, pursuant to the Private Placement Warrants Purchase Agreements, the Company completed the private sale of an aggregate of 5,066,666 warrants (the “ Private Placement Warrants ”) to the Sponsor, Sternship and the Underwriters at a purchase price of $1.50 per Private Placement Warrant, generating gross proceeds to the Company of $7,600,000.”

OLENOX INDUSTRIES INC. issued 900 shares of Series C Preferred Stock of preferred stock to institutional investor for aggregate purchase price of $810,000.

“At the Second Closing, the Company issued and sold to the Purchaser 900 shares of Series C Preferred Stock (the “Additional Preferred Shares”), representing an aggregate Stated Value of $900,000, for an aggregate purchase price of $810,000.”

BIOXYTRAN, INC issued preferred stock.

“The Company approved and filed an amendment to the Certificate of Designation of Convertible Preferred Stock to modify the conversion provisions of the Company’s Preferred Stock.”

Equillium, Inc. issued pre-funded warrant to purchase up to 17,698,593 Warrant Shares at $0.0001 exercise price of warrant to RA Capital Healthcare Fund, L.P. for purchase price of $1.8539 per Warrant Share.

“a pre-funded warrant to purchase up to 17,698,593 Warrant Shares at a purchase price of $1.8539 per Warrant Share (the “Warrant Price”) to the Investor for gross proceeds to the Company of approximately $35.0 million.”

Equillium, Inc. issued 1,179,508 Shares at $1.854 per share of common stock to RA Capital Healthcare Fund, L.P. for gross proceeds of approximately $35.0 million.

“up to 17,698,593 Warrant Shares at a purchase price of $1.8539 per Warrant Share (the “Warrant Price”) to the Investor for gross proceeds to the Company of approximately $35.0 million. The pre-funded warrant will have an exercise price of $0.0001 per Warrant Share, subject to customary adjustments, and will be exercisable at any time after original issuance”

TruGolf Holdings, Inc. issued preferred stock.

“At the Effective Time, each share of Class A Common Stock, par value $0.0001 per share (the “Delaware Class A Common Stock”), each share of Class B Common Stock, par value $0.0001 per share (the “Delaware Class B Common Stock”), and each share of Series A Preferred Stock, par value $0.0001 per share (the “Delaware Series A Preferred Stock”), issued and outstanding immediately prior to the Effective Time was converted into one share of Class A Common Stock, par value $0.0001 per share (the “Nevada Class A Common Stock”), one share of Class B Common Stock, par value $0.0001 per share (the “Nevada Class B Common Stock”), and one share of Series A Preferred Stock, par value $0.0001 per share (the “Nevada Series A Preferred Stock”), respectively, of the Nevada Corporation.”

SUMA Acquisition Corp issued 446,250 units of unit to SUMA Sponsor LP, SUMA Canada II Sponsor LP, and Seaport Global Securities LLC for $10.00 per Private Placement Unit for an aggregate purchase price of $4,462,500.

“the Company completed the private sale of an aggregate of 446,250 units (the “Private Placement Units”) to the Sponsor and Seaport at a price of $10.00 per Private Placement Unit for an aggregate purchase price of $4,462,500.”

PARKERVISION INC issued 3,277,099 shares of common stock to certain holders of outstanding convertible promissory notes for exchange for cancellation of Exchange Notes having aggregate outstanding principal amount of $675,000 and accrued and unpaid interest of approximately $13,200.

“On March 13, 2026, the Company issued an aggregate of 3,277,099 shares of its Common Stock to the Holders in exchange for the cancellation of Exchange Notes having an aggregate outstanding principal amount of $675,000 and accrued and unpaid interest of approximately $13,200.”

Laird Superfood, Inc. issued 50,000 Initial Shares of Series A Preferred Stock of preferred stock to Nexus Investment for $50.0 million in gross proceeds.

“on the Closing Date, the Investor purchased the Initial Shares from the Company for gross proceeds of $50.0 million.”

APPlife Digital Solutions Inc issued convertible note to an investor for principal amount of $60,000, including a $6,000 original issue discount for a purchase price of $54,000.

“On March 9, 2026, the Company issued a convertible Promissory Note to an investor, with a principal amount of $60,000, including a $6,000 original issue discount for a purchase price of $54,000.”

Beneficient issued 149,904 shares of common stock to HH-BDH, LLC for aggregate value of $572,588.

“the Company agreed to issue HH-BDH 149,904 shares of the Company’s Class A common stock, par value $0.001 per share (the “Class A common stock” and such shares, the “HH-BDH Shares”), having an aggregate value of $572,588 based on the five-day volumed-weighted average price per share of the Class A common stock on March 10, 2026”

Aptera Motors Corp issued up to 4,751,250 shares of Common Stock of warrant to holders of certain existing warrants for $3.50 per share.

“of the number of shares of Common Stock issued upon exercise of the Existing Warrants (the “Inducement Warrant Shares”). The Inducement Warrants will have an exercise price of $3.50 per share, will be exercisable immediately and will expire on the five-year anniversary of their issuance date. The Company has agreed to file a registration statement within ten”

Xilio Therapeutics, Inc. issued common stock.

“will implement a 1-for-14 reverse stock split of the issued shares of the company’s common stock, effective at 5:00 p.m. Eastern Time on March 13, 2026.”

FLYEXCLUSIVE INC. issued 451,901 shares of common stock to Volato Group, Inc. and its subsidiaries for $1,333,333 aggregate purchase price.

“Agreement include cash and cash equivalents, bank accounts and other excluded assets described in Section 1.3 of the Purchase Agreement. The aggregate purchase price was $1,333,333, which the Company paid in 451,901 shares of its Class A common stock based on a volume-weighted average price of $2.9505 per share as of the Closing Date, as calculated pursuant”

ESG Inc. issued 18,333 shares of warrant to Crom Structured Opportunities Fund I, LP for $6.00 per share.

“issued a common stock purchase warrant to purchase 18,333 shares of the Company’s common stock at an exercise price of $6.00 per share (the “Crom Warrant”)”

ESG Inc. issued convertible note to Crom Structured Opportunities Fund I, LP for $100,000 in gross proceeds.

“the Company issued a convertible promissory note in the principal amount of $110,000 in exchange for $100,000 in gross proceeds (the “Crom Note”)”

ESG Inc. issued 18,333 shares of warrant to Monroe Street Capital Partners, LP for $6.00 per share.

“issued a common stock purchase warrant to purchase 18,333 shares of the Company’s common stock at an exercise price of $6.00 per share (the “Monroe Warrant”)”

ESG Inc. issued convertible note to Monroe Street Capital Partners, LP for $100,000 in gross proceeds.

“the Company issued a convertible promissory note in the principal amount of $110,000 in exchange for $100,000 in gross proceeds (the “Monroe Note”)”

FIREFLY NEUROSCIENCE, INC. issued 1,500,000 Units of unit to accredited investors for $2,250,000.

“On March 12, 2026, the Initial Closing under the Purchase Agreement occurred, and the Company issued 1,500,000 Units to the Investors at a total purchase price of $2,250,000.”

SONIDA SENIOR LIVING, INC. issued 1,031,250 warrants of warrant to Conversant Dallas Parkway (A) LP and Conversant Dallas Parkway (B) LP.

“extend the expiration date of the Warrants from November 3, 2026 to November 3, 2027”

SONIDA SENIOR LIVING, INC. issued 41,250 outstanding shares of Series A Convertible Preferred Stock of preferred stock to Conversant Dallas Parkway (A) LP and Conversant Dallas Parkway (B) LP for reduced conversion price from $40.00 to $32.00 per share of Common Stock.

“outstanding shares of Series A Convertible Preferred Stock and all of the 1,031,250 warrants to purchase Company common stock, par value $0.01 per share (“Common Stock”), for $40.00 per share (the “Warrants”) issued and outstanding under that certain Warrant Agreement, dated as of November 3, 2021 (the “Warrant Agreement”), by and among the Company,”